<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929888</url>
  </required_header>
  <id_info>
    <org_study_id>2016-ECCLIPSESTEMI-01</org_study_id>
    <nct_id>NCT02929888</nct_id>
  </id_info>
  <brief_title>Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients</brief_title>
  <acronym>ECCLIPSE-STEMI</acronym>
  <official_title>Effects of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Platelet Responsiveness in Patients With ST-segment Elevation Myocardial Infarction: a Pharmacodynamic Study (ECCLIPSE-STEMI Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Investigacion Interhospitalaria Cardiovascular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Investigacion Interhospitalaria Cardiovascular</source>
  <brief_summary>
    <textblock>
      Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater
      pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute
      coronary syndrome. However, evidence is lacked about the effects of achieving faster and
      stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to
      oral aspirin on prasugrel inhibited platelets. Recently, we demonstrated in healthy
      volunteers that the administration of intravenous LA resulted in a significantly reduction of
      platelet reactivity compared to oral aspirin on prasugrel inhibited platelets. Loading dose
      of LA achieves platelet inhibition faster, greater and with less variability than aspirin.
      However, there are no data of this issue in patients with an ST-segment elevation myocardial
      infarction (STEMI). The ECCLIPSE-STEMI trial will study the effect of LA versus aspirin in
      platelet reactivity in patients with STEMI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single-center, open platelet function study conducted in
      60 STEMI patients. Subjects were randomly assigned to receive a loading dose (LD) of
      intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg, or LD of aspirin 300mg plus
      prasugrel 60mg/ticagrelor 180mg orally. Platelet function was evaluated at baseline, 30 min,
      1h, 4h, and 24h using multiple electrode aggregometry and vasodilator-stimulated
      phosphoprotein phosphorylation (VASP). The primary endpoint of the study is the inhibition of
      platelet aggregation after arachidonic acid (AA) 1.5mM at 30 min. Secondary endopoints are
      the inhibition of platelet aggregation after AA baseline and at 1h, 4h and 24h, and
      measurement of aggregation with other platelet test (ADP, collagen and VASP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>30 min</time_frame>
    <description>The primary endpoint of the study, inhibition of platelet aggregation after arachidonic acid (AA) 1.5mM at 30 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of platelet aggregation</measure>
    <time_frame>30 min, 1h, 4h, 24h</time_frame>
    <description>Inhibition of platelet aggregation using different platelet function test (ADP, collagen, VASP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Lysine Acetilsalicilate (LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lysine Acetilsalicilate</intervention_name>
    <arm_group_label>Lysine Acetilsalicilate (LA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &gt; 18.

          -  Patients with ST-segment myocardial infarction.

          -  Signed written informed consent.

        Exclusion Criteria:

          -  Known allergies to aspirin, clopidogrel, prasugrel or ticagrelor.

          -  Cardiogenic shock or hemodinamic instability.

          -  Recent antiplatelet therapy (&lt;14 days).

          -  Oral anticoagulation with a coumarin derivative.

          -  Any active bleeding or blood dyscrasia.

          -  Recent gastrointestinal bleeding (&lt;6 months prior to inclusion).

          -  Recent history of stroke, TIA or intracranial bleeding (&lt;6 months prior to inclusion).

          -  Known anemia, trombopenia or severe chronic kidney/liver disease

          -  Any known active neoplasm.

          -  Pregnant females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Vivas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Carlos University Hospital, Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Vivas, MD, PhD</last_name>
    <phone>0034 913303149</phone>
    <phone_ext>3149</phone_ext>
    <email>dvivas@secardiologia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vivas, MD, PhD</last_name>
      <phone>0034913303149</phone>
      <phone_ext>3149</phone_ext>
      <email>dvivas@secardiologia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Investigacion Interhospitalaria Cardiovascular</investigator_affiliation>
    <investigator_full_name>David Vivas</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ST-segment elevacion myocardial infarction, platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Acetylsalicylic acid lysinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

